近年来，随着对肿瘤生物学机制探索的不断深入，以及免疫治疗、抗体偶联药物（ADC）、双特异性抗体等新型疗法的涌现，小细胞肺癌（SCLC）的治疗迎来重大突破，已从单一的化疗时代迈向精准分型与联合治疗的新阶段。2026年欧洲肺癌大会（ELCC 2026）定于2026年3月25日至28日在丹麦哥本哈根举行。近日，其官网公布了部分入选摘要信息，包含多项SCLC免疫治疗及靶向DLL3等创新药物研究进展。《肿瘤瞭望》现对相关研究信息进行整理，以飨读者。

局限期小细胞肺癌（LS-SCLC）

摘要号：410P

英文标题：Subsequent treatment (tx) patterns and impact on patient (pt) outcomes in the phase 3 ADRIATIC study of consolidation durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage SCLC (LS-SCLC)

中文标题：局限期小细胞肺癌同步放化疗后度伐利尤单抗巩固治疗的III期ADRIATIC研究：后续治疗模式及其对患者结局的影响

摘要号：411P

英文标题：Serplulimab Consolidation after Concurrent Hypofractionated Chemoradiotherapy for Limited-stage Small-cell Lung Cancer

中文标题：信迪利单抗用于局限期小细胞肺癌大分割同步放化疗后的巩固治疗

广泛期小细胞肺癌（ES-SCLC）一线治疗

摘要号：408O

英文标题：Phase II Study of iza-bren (BL-B01D1) in Combination with Serplulimab in Patients with Small Cell Lung Cancer (SCLC)

中文标题：Iza-bren（BL-B01D1）联合斯鲁利单抗治疗小细胞肺癌患者的II期研究

讲者：周斐 教授（同济大学附属东方医院）

摘要号：418P

英文标题：Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC): 5-year update of the phase 3 CAPSTONE-1 study

中文标题：Adebrelimab联合化疗一线治疗广泛期小细胞肺癌：III期CAPSTONE-1研究5年更新结果

摘要号：419P

英文标题：7-y survival in patients (pts) with extended-stage small cell lung cancer (ES-SCLC) treated with atezolizumab (atezo) in the IMpower133 (IMp133) and IMbrella A extension study, including brain (BM) and liver metastases (LM) by SCLC molecular subtype

中文标题：IMpower133研究及IMbrella A扩展研究中阿替利珠单抗治疗的广泛期小细胞肺癌患者7年生存情况：按分子亚型分析脑转移与肝转移患者

摘要号：421P

英文标题：Survival Benefit of Long-Term (Beyond 2 Years) Atezolizumab in 1L ES-SCLC: Exploratory Analysis of Four Phase 3 Trials

中文标题：阿替利珠单抗长期一线治疗（超过2年）广泛期小细胞肺癌的生存获益：四项III期试验的探索性分析

摘要号：423P

英文标题：IMforte: Subsequent Treatment (Tx) Following First-Line Maintenance (1Lm) With Lurbinectedin (Lurbi) + Atezolizumab (Atezo) or Atezo in Extensive Stage Small Cell Lung Cancer (ES-SCLC)

中文标题：IMforte研究：Lurbinectedin联合阿替利珠单抗或阿替利珠单抗单药一线维持治疗广泛期小细胞肺癌后的后续治疗

摘要号：426P

英文标题：Phase 2 Study of First-Line Pumitamig (PD-L1 × VEGF-A bsAb) Plus Chemotherapy for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): Updated Efficacy and Safety Results

中文标题：Pumitamig（PD-L1×VEGF-A双特异性抗体）联合化疗一线治疗广泛期小细胞肺癌的II期研究：疗效与安全性更新结果

摘要号：427P

英文标题：Interim Results of a Randomized Phase II Trial of Trilaciclib Combined with Envafolimab, Etoposide, and Carboplatin as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

中文标题：Trilaciclib联合Envafolimab、依托泊苷及卡铂一线治疗广泛期小细胞肺癌的II期随机试验中期结果

摘要号：434P

英文标题：Myeloprotection with Trilaciclib Prior to First-Line Chemotherapy in Extensive-Stage Small Cell Lung Cancer: An Integrated Analysis of Clinical Trials

中文标题：曲拉西利在广泛期小细胞肺癌一线化疗前的骨髓保护作用：临床试验整合分析

摘要号：437P

英文标题：Immunotherapy in ES-SCLC: Real-World Impact of Atezolizumab/Durvalumab, Radiotherapy, and Metastatic Burden Across ECOG 0-2 Patients

中文标题：广泛期小细胞肺癌的免疫治疗：阿替利珠单抗/度伐利尤单抗、放疗及转移负荷对ECOG 0-2分患者的真实世界影响

摘要号：439TiP

英文标题：ROSETTA Lung-01: A Phase 3, Two-Stage Trial of Pumitamig, a PD-L1 × VEGF-A Bispecific Antibody, Plus Chemotherapy Versus Atezolizumab + Chemotherapy as First-Line Treatment in Patients With Extensive-Stage Small Cell Lung Cancer

中文标题：ROSETTA Lung-01研究：Pumitamig（PD-L1×VEGF-A双特异性抗体）联合化疗对比阿替利珠单抗联合化疗一线治疗广泛期小细胞肺癌的III期两阶段试验

摘要号：440TiP

摘要号：441TiP

英文标题：SEZanne: A phase 2 randomized, open-label, multicenter study to evaluate the optimal dose, safety, and efficacy of ABBV-706 in combination with atezolizumab (atezo) versus standard of care (SOC) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC)

中文标题：SEZanne研究：ABBV-706联合阿替利珠单抗对比标准治疗用于初治广泛期小细胞肺癌的II期随机开放标签多中心研究：最佳剂量、安全性及疗效评估

摘要号：442TiP

英文标题：DeLLphi-312 Phase 3 Trial-in-Progress: Tarlatamab With Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide As First-Line (1L) Therapy in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

中文标题：III期在研DeLLphi-312试验：Tarlatamab联合度伐利尤单抗、卡铂及依托泊苷对比度伐利尤单抗联合卡铂及依托泊苷一线治疗广泛期小细胞肺癌

摘要号：443TiP

英文标题：Maintenance therapy with adebrelimab plus vunakizumab for ES-SCLC after first-line induction with adebrelimab and chemotherapy: a prospective, single-arm, phase II clinical study

中文标题：Adebrelimab联合化疗一线诱导治疗后，Adebrelimab联合vunakizumab巩固治疗广泛期小细胞肺癌的前瞻性单臂II期临床研究

复发/难治性小细胞肺癌后线治疗

摘要号：409O